SIR Policy on Off-label Use of Devices and Drugs

The scientific program of the SIR Annual Scientific Meeting shall be developed with the goal of satisfying the overall educational objectives of the annual meeting. The content of the scientific program will be developed solely by the physician members of the SIR Annual Meeting Committee in accordance with the ACCME Standards for Commercial Support of Continuing Medical Education. Commercial supporters and their representations will not participate in the development of the meeting content except to respond to requests for technical assistance with the preparation of conference-related educational materials. Such materials may not, by their content of format, advance the specific proprietary interests of the commercial supporter. Commercial supporters may also provide names of suggested speakers in response to specific requests by SIR for such information.


Presentations during the scientific program are considered to represent the work and opinions of the speaker, and do not necessarily reflect the views or policies of SIR. The SIR annual meeting provides a forum for these presentations in order to educate and promote the dissemination of new ideas, but SIR does not necessarily endorse the findings or conclusions reported by the speaker.


Faculty at the SIR Annual Scientific Meeting are required to inform the audience when they are discussing off-label or unapproved uses of new devices or drugs. Devices or drugs that are still undergoing clinical trials should also be identified as such and should not be portrayed as standard, accepted therapy. Faculty are also required to disclose any significant financial relationships they have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Such relationships must also be disclosed in promotional materials for the annual meeting.


Exhibitors at the SIR Annual Scientific Meeting are required to comply with all applicable FDA regulations and ACCME standards, including but not limited to any and all approval requirements and the FDA's prohibition on advertising or other promotion of investigational or unapproved drugs or devices. FDA also forbids manufacturers and distributors from promoting approved drugs and devices for unapproved uses.


Representatives of commercial supporters may attend SIR educational presentations, but may not engage in sales activities while in the room where the activity takes place.

Approved by the SIR Executive Council, November 1997